Importantly, several progranulin-elevating drugs are currently under investigation in clinical trials for treatment of FTLD-GRN71, and they could be repurposed for treatment of FXS patients and other ASD patients associated with reduced number or hypoactivity of PV neurons. Here, GRN is linked to fragile X syndrome.